In addition to the CD4+ T cell count, Powls et al. identified an association between the treatment with the non-nucleoside reverse transcriptase inhibitor efavirenz and HL risk, whereas more recent investigations did not identify an association between EFV and HL risk [84–86]. This evidence concerns the gene CD4 and Hodgkins lymphoma.